Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial (Q28304807)

17

object named as

Michelle A Petri

0 references

author name string

Sandra V Navarra

1

0 references

Renato M Guzmán

2

0 references

Alberto E Gallacher

3

0 references

Stephen Hall

4

0 references

Renato E Jimenez

6

0 references

Edmund K-M Li

7

0 references

Mathew Thomas

8

0 references

Ho-Youn Kim

9

0 references

Manuel G León

10

0 references

Coman Tanasescu

11

0 references

Eugeny Nasonov

12

0 references

Joung-Liang Lan

13

0 references

Lilia Pineda

14

0 references

Z John Zhong

15

0 references

William Freimuth

Systemic lupus erythematosus.

16

0 references

language of work or name

English

0 references

publication date

26 February 2011

0 references

published in

The Lancet

0 references

volume

377

0 references

page(s)

721-31

0 references

issue

9767

0 references

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2961354-2

7 January 2021

Mortality in systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2961354-2

7 January 2021

Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2961354-2

7 January 2021

Infections as triggers and complications of systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2961354-2

7 January 2021

Two aspects of the clinical and humanistic burden of systemic lupus erythematosus: mortality risk and quality of life early in the course of disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2961354-2

7 January 2021

BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2961354-2

7 January 2021

The role of B lymphocyte stimulator (BLyS) in systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2961354-2

7 January 2021

Cracking the BAFF code.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2961354-2

7 January 2021

Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2961354-2

7 January 2021

The level of BLyS (BAFF) correlates with the titre of autoantibodies in human Sjögren's syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2961354-2

7 January 2021

Cutting edge: a role for B lymphocyte stimulator in systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2961354-2

7 January 2021

B lymphocyte stimulator (BLyS) isoforms in systemic lupus erythematosus: disease activity correlates better with blood leukocyte BLyS mRNA levels than with plasma BLyS protein levels

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2961354-2

7 January 2021

Association of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2961354-2

7 January 2021

Generation and characterization of LymphoStat‐B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2961354-2

7 January 2021

Chronic administration of belimumab, a BLyS antagonist, decreases tissue and peripheral blood B-lymphocyte populations in cynomolgus monkeys: pharmacokinetic, pharmacodynamic, and toxicologic effects

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2961354-2

7 January 2021

A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2961354-2

7 January 2021

Novel evidence-based systemic lupus erythematosus responder index

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2961354-2

7 January 2021

New directions in the treatment of systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2961354-2

7 January 2021

Lessons learned from clinical trials in SLE.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2961354-2

7 January 2021

Clinical trials in systemic lupus erythematosus (SLE): lessons from the past as we proceed to the future--the EULAR recommendations for the management of SLE and the use of end-points in clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2961354-2

7 January 2021

Systemic lupus erythematosus clinical trials-an interim analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2961354-2

7 January 2021

Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2961354-2

7 January 2021

Combined oral contraceptives in women with systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2961354-2

7 January 2021

Classification and definition of major flares in SLE clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2961354-2

7 January 2021

From BILAG to BLIPS--disease activity assessment in lupus past, present and future

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2961354-2

7 January 2021

Definition and treatment of lupus flares measured by the BILAG index

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2961354-2

7 January 2021

Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2961354-2

7 January 2021

Decreases in anti-double-stranded DNA levels are associated with concurrent flares in patients with systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2961354-2

7 January 2021

British Isles Lupus Assessment Group 2004 index is valid for assessment of disease activity in systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2961354-2

7 January 2021

EULAR recommendations for the management of systemic lupus erythematosus. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2961354-2

7 January 2021

The impact of flare on disease costs of patients with systemic lupus erythematosus.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2961354-2

7 January 2021

Damage in systemic lupus erythematosus and its association with corticosteroids

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2961354-2

7 January 2021

Treatment of lupus with corticosteroids

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2961354-2

7 January 2021

10.1016/S0140-6736(10)61354-2

Identifiers

DOI

1 reference

Consolidated OpenCitations Corpus – April 2017

1836975

1836975

1 reference

Consolidated OpenCitations Corpus – April 2017

Consolidated OpenCitations Corpus – April 2017

1 reference